Monday, November 17, 2025

 

Parasitic matricide, ants chemically compel host workers to kill their own queen



Researchers detail a parasitic strategy, first observed in a blog post, where an invading ant queen uses a chemical spray to compel host workers into killing their own mother



Kyushu University

An ant colony rises against its own queen 

image: 

Researchers report on a behavioral phenomenon where parasitic ants trick a host colony into killing its own queen. In this photo, the parasitic ant queen Lasius orientalis (left) infiltrates the nest of Lasius flavus and apporaches their queen (right). The parasite will then spray the host queen and trick the colony to attacking their own mother. Once the host queen is dispatched, the parasitic queen will take over.

view more 

Credit: Keizo Takasuka/Kyushu University





Fukuoka, Japan—In the ruthless world of parasitic ants, taking over a host colony is a matter of life and death. The conventional understanding has been that an invading queen must physically fight and kill the resident queen to seize control. However, a new study published in Current Biology details a more sinister strategy: a parasitic ant queen that chemically manipulates the host colony’s workers into executing their own mother.

“The initial discovery was made by my friend Taku Shimada, the first author of the paper, who has been passionate about ants since childhood and runs a popular blog called ‘AntRoom.’ He observed the colony infiltration and posted about it in 2021,” explains Assistant Professor Keizo Takasuka of Kyushu University’s Faculty of Science, the corresponding author on the paper. “I found the post three years later and was so astonished. I thought it was a very valuable discovery that deserved to be documented as academic knowledge.”

The chemical manipulation was documented in two distantly related species of parasitic ants and their hosts: Lasius orientalis, which infiltrates the nests of Lasius flavus; and Lasius umbratus, which invades the colonies of Lasius japonicus.

“The parasitic behavior of the latter species of ants was discovered by Yuji Tanaka, who is the second author of this study. He is another enthusiastic amateur of ants and followed the same observational methods established by Shimada,” explains Takasuka.

In the case of Lasius orientalis, the parasite sprayed the host colony queen repeatedly, about 15 times over 20 hours. This slowly agitated the host workers, who began attacking their queen, eventually mutilating and killing her after four days.

The Lasius umbratus queen, however, used only two targeted sprays. This was enough to incite an immediate and fatal attack from the host workers, who proceeded to dismember their queen. In both cases, after the matricide, the host workers accepted the parasitic queen, who soon began laying her own eggs to be cared for by the orphaned colony.

The researchers suggest this fluid was formic acid, a well-known defensive compound used by many ant species to deter predators or as a warning signal to fellow nestmates. In this context, it appears to act as a deceptive social signal.

“In both cases, the host and parasite belong to the same genus, so they both have formic acid and recognize it as a danger signal,” states Takasuka. “We believe that when their queen is suddenly covered in a large amount of this chemical, the workers perceive their own mother as a colony-threatening crisis which triggers their aggressive defensive behavior.”

To get close enough to perform this manipulation, the parasite must first bypass the colony’s guards. The researchers replicated this step in their experiments through a process called host-odor pre-acquisition.

“Direct infiltration would fail because the workers would immediately perceive the intruder and attack her,” continues Takasuka. “To achieve this, the parasitic queen was housed with a few host workers and cocoons. After just one night, she acquired the host colony’s specific scent, providing a chemical camouflage that was essential for her to get past the initial defenses.”

Interestingly, even though these two parasitic ant species are not close relatives, they share the same genus that is known to have two discrete origins of social parasitism. Takasuka explains that these behaviors are an example of convergent evolution, where similar traits develop independently between unrelated species.

“My own research focuses on how parasitoid wasps manipulate the behavior of spiders, so I know that in the natural world, parasitic organisms utilize many various and interesting strategies to infect their hosts,” concludes Takasuka. “This discovery in ants is another fascinating example. I am interested in investigating these different host-killing strategies to understand the evolutionary pressures that drive them.”

A full video showing the ants and their behavior can be found here.

###

For more information about this research, see "Socially parasitic ant queens chemically induce queen-matricide in host workers," Taku Shimada, Yuji Tanaka, Keizo Takasuka, Current Biologyhttps://doi.org/10.1016/j.cub.2025.09.037

 

Clinical trials affected by research grant terminations at the National Institutes of Health



JAMA Internal Medicine




About The Study: 

Approximately 1 in 30 trials and more than 74,000 trial participants were affected by grant funding disruptions. Affected trials disproportionately studied infectious diseases, prevention, and behavioral interventions, and were based in the Northeastern U.S. or in other countries. Because trials require sustained financial support to ensure operations and participant safety, unanticipated funding disruptions raise concerns about avoidable waste, data quality, and compromised ethical obligations to participants. 



Corresponding Author: To contact the corresponding author, Anupam B. Jena, MD, PhD, email jena@hcp.med.harvard.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamainternmed.2025.6088)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article 

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.6088?guestAccessKey=592ff841-f9a4-498e-987d-6b8c5eab0bef&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111725

 

Do all countries benefit from clinical trials? A new Yale study examines the data



Yale University





A new study led by Yale’s Jennifer Miller, PhD, found that medicines are not physically accessible in many of the countries where they are tested for FDA approval.

The findings were published in JAMA Internal Medicine.

 

For the study, researchers analyzed 172 FDA-approved medicines tested between 2015 and 2018 in nearly 90 countries. They found that five years after testing, only 24 percent of the medicines had received market authorization, or approval for distribution and patient access, in the countries where the clinical trials were conducted. High-income countries had greater physical access to the medicines than upper-middle- and lower-middle-income countries.

“This gap raises concerns,” says Miller, an associate professor of medicine (general medicine) and co-director of the Program for Biomedical Ethics at Yale School of Medicine. “According to ethical guidance, if you enroll a population in clinical research, they must stand to benefit from it.”

The principle Miller references — distributive justice — is embedded in major ethical frameworks such as the World Medical Association Declaration of Helsinki, adopted in 1964, and the Council for International Organizations of Medical Sciences International Guidelines for Health-related Research Involving Humans, published in 2016.

Yet, according to Miller, these guidelines are vague. “There’s enough ambiguity that, if someone wanted to get around it, they could,” she says.

 

Study co-author Cary Gross, MD, professor of medicine (general medicine), adds that people enroll in clinical trials for many reasons, including the opportunity to contribute to scientific progress. “But there is also a frequently unstated part of this ‘bargain’ — that if the new treatment works, then presumably people in your community — or country — will be able to access it,” he says. 

 

The study’s findings confirm that many countries still host trials without ever gaining timely access to the medicines they help test. To address this, Miller is expanding the Good Pharma Scorecard, an index she founded that rates and ranks companies on ethical performance — from data transparency to, soon, post-trial access.

 

“The scorecard sets clear goals for the sector,” she explains. “It defines what a good ethical company looks like, tracks progress, and makes the results public. When companies see their rankings, half of them improve within 30 days. We’re hoping to use that same incentive design to close the access gap.”

Miller’s team is also studying what she refers to as “bright spots” — countries like Ethiopia and Uganda that managed to secure full access to the medicines they helped test. With support from a Yale and the World grant, she plans to bring health ministers and clinical trial leaders from those countries to campus to share lessons with peer nations.

Ultimately, Miller says, fixing the “test it (but) don’t sell it” problem will require collective effort. “Pharma companies have to change, countries need to be empowered, and the media, NGOs, and patient organizations have to stay engaged,” she says. “We need all hands on deck.”

 

 

From artificial organs to advanced batteries: A breakthrough 3D-printable polymer




University of Virginia School of Engineering and Applied Science
Liheng Cai lab's 3D-printed polymer structures collage 

image: 

Liheng Cai’s foldable bottlebrush polymers can yield a variety of material structures with different properties that could enable applications from organ transplants to battery technology.

view more 

Credit: Liheng Cai/Softbiomatter Lab/University of Virginia





A new type of 3D-printable material that gets along with the body’s immune system, pioneered by a University of Virginia research team, could lead to safer medical technology for organ transplants and drug delivery systems. It could also improve battery technologies.

The breakthrough is the subject of a new article in the journal Advanced Materials, based on work done by the University of Virginia’s Soft Biomatter Laboratory, led by Liheng Cai, an associate professor of materials science and engineering and chemical engineering. 

The paper’s first author is Baiqiang Huang, a Ph.D. student in the School of Engineering and Applied Science.

Their research shows a way to change the properties of polyethylene glycol to make stretchable networks. PEG, as it’s known, is a material already used in many biomedical technologies such as tissue engineering, but the way PEG networks are currently produced — created in water by crosslinking linear PEG polymers, with the water removed afterward — leaves a brittle, crystallized structure that can’t stretch without losing its integrity. 

The breakthrough in elasticity is an important feature, because stretchiness would allow PEG networks’ use in larger structures, or in structures that require some flexibility and movement, such as the scaffolding needed someday for synthetic human organs. 

Stretch Lies in Foldable Design

To create this stretchiness, the team built upon existing work from Cai’s lab, which had already developed a way to create very strong synthetic polymers. The approach took a page from the methods used to create stretchy, strong rubber: store length in internal structures at the molecular level. 

These internal structures, called a “foldable bottlebrush” design, make for a material that can be both very strong and very stretchy. The polymeric molecules have many flexible side chains radiating out from a central backbone that can collapse like an accordion — storing extra length that can be unfolded.

“Our group discovered this polymer and used this architecture to show any materials made this way are very stretchable.” Cai said.

To create the new material described in Advanced Materials, Huang applied the foldable bottlebrush polymer concept to PEG. He exposed the precursor mixture to ultraviolet light for a few seconds, which initiates polymerization to form a bottlebrush-architecture network. This resulted in 3D-printable, highly stretchable PEG-based hydrogels and solvent-free elastomers. 

“We can change the shape of the UV lights to create so many complicated structures,” Huang said, including structures that are either soft or stiff but remain stretchy by design. This type of versatility in design could one day allow for the creation of new techniques for creating artificial organs or delivery medicines. 

The paper also shows that the stretchy 3D-printable PEG materials are biologically friendly. The researchers cultured cells alongside the materials, to make sure they can live side-by-side, and they were compatible, Huang said. This is good news for its potential use for materials that would go inside the body, such as scaffolding for an organ. 

Future Applications

In a future application, it might also be possible to combine PEG with other materials to create 3D-printable materials with different chemical compositions, opening the door to many possible uses. 

For example, compared to existing materials for solid-state polymer electrolytes, the new materials show greater electrical conductivity and much higher stretchability at room temperature. 

“This property highlights the new material as a promising high-performance solid-state electrolyte for advanced battery technologies,” Cai said. “Our team continues to explore potential extensions of the research in solid-state battery technologies.” 

The paper’s other authors include UVA Engineering colleagues Myoeum Kim, Pu Zhang, Emmanuel Oduro and Daniel A. Rau. The work was funded by the National Science Foundation, National Institutes of Health, UVA LaunchPad for Diabetes and Virginia Innovation Partnership Corporation’s Commonwealth Commercialization fund. 

The paper, “Additive Manufacturing of Molecular Architecture Encoded Stretchable Polyethylene Glycol Hydrogels and Elastomers,” was published in Advanced Materials on Oct. 29.